Literature DB >> 9563065

Drug exsorption from blood into the gastrointestinal tract.

K Arimori1, M Nakano.   

Abstract

Drugs are exsorbed from the blood across the gastrointestinal membranes by passive or active processes. In the case of a passive transport mechanism, the exsorption of drugs depends on the concentration gradients between the serosal and mucosal sides. The extent of secretion (exsorption) is determined by numerous factors such as extent of binding to serum proteins, distribution volume, lipophilicity, pKa and molecular size of drugs, and the blood flow rate in the gut. Specific transport systems such as P-glycoprotein (P-gp), organic cation and organic anion transporters are found to be involved in active intestinal secretion of drugs. Intestinal secretory transport systems reduce the extent of drug absorption sometimes resulting in low oral bioavailability. It is, therefore, important to know whether poor drug absorption is due to the involvement of specialized secretory transport systems. Modulation of intestinal secretory transport can be a means to enhance absorption of drugs with low oral bioavailability if exsorption of drugs is based on active secretion pathways that are open for control from the "outside".

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9563065     DOI: 10.1023/a:1011959828103

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  50 in total

1.  Gastrointestinal dialysis of disopyramide in healthy subjects.

Authors:  K Arimori; H Kawano; M Nakano
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1989-06

2.  The contribution of solvent drag to the intestinal absorption of the acidic drugs benzoic acid and salicylic acid from the jejunum of the rat.

Authors:  H Ochsenfahrt; D Winne
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

3.  Permeability of the small intestine to substances of different molecular weight.

Authors:  C A Loehry; A T Axon; P J Hilton; R C Hider; B Creamer
Journal:  Gut       Date:  1970-06       Impact factor: 23.059

4.  In vivo disposition and metabolism by liver and enterocyte microsomes of the antitubercular drug rifabutin in rats.

Authors:  T Koudriakova; E Iatsimirskaia; S Tulebaev; D Spetie; I Utkin; D Mullet; T Thompson; P Vouros; N Gerber
Journal:  J Pharmacol Exp Ther       Date:  1996-12       Impact factor: 4.030

5.  Evidence for a polarized efflux system in CACO-2 cells capable of modulating cyclosporin A transport.

Authors:  P F Augustijns; T P Bradshaw; L S Gan; R W Hendren; D R Thakker
Journal:  Biochem Biophys Res Commun       Date:  1993-12-15       Impact factor: 3.575

6.  Increased transport of theophylline into gastrointestinal lumen and gastrointestinal dialysis by activated charcoal in rats with hepatic cirrhosis.

Authors:  K Arimori; K Wakayama; M Nakano
Journal:  Chem Pharm Bull (Tokyo)       Date:  1989-11       Impact factor: 1.645

7.  Energy-dependent transport of digoxin across renal tubular cell monolayers (LLC-PK1).

Authors:  S Ito; G Koren; P A Harper; M Silverman
Journal:  Can J Physiol Pharmacol       Date:  1993-01       Impact factor: 2.273

8.  Mixed-effect modeling for detection and evaluation of drug interactions: digoxin-quinidine and digoxin-verapamil combinations.

Authors:  L A Bauer; J R Horn; H Pettit
Journal:  Ther Drug Monit       Date:  1996-02       Impact factor: 3.681

Review 9.  P-glycoprotein and pharmacokinetics.

Authors:  D Levêque; F Jehl
Journal:  Anticancer Res       Date:  1995 Mar-Apr       Impact factor: 2.480

10.  The function of Gp170, the multidrug-resistance gene product, in the brush border of rat intestinal mucosa.

Authors:  S Hsing; Z Gatmaitan; I M Arias
Journal:  Gastroenterology       Date:  1992-03       Impact factor: 22.682

View more
  13 in total

1.  Estimation of molecular linear free energy relationship descriptors. 4. Correlation and prediction of cell permeation.

Authors:  J A Platts; M H Abraham; A Hersey; D Butina
Journal:  Pharm Res       Date:  2000-08       Impact factor: 4.200

2.  Transepithelial transport of diphenhydramine across monolayers of the human intestinal epithelial cell line Caco-2.

Authors:  H Mizuuchi; T Katsura; Y Hashimoto; K Inui
Journal:  Pharm Res       Date:  2000-05       Impact factor: 4.200

3.  Excretion into gastrointestinal tract of irinotecan lactone and carboxylate forms and their pharmacodynamics in rodents.

Authors:  K Arimori; N Kuroki; A Kumamoto; N Tanoue; M Nakano; E Kumazawa; A Tohgo; M Kikuchi
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

4.  Involvement of multidrug resistance-associated protein 2 in intestinal secretion of grepafloxacin in rats.

Authors:  Kazumasa Naruhashi; Ikumi Tamai; Natsuko Inoue; Hiromi Muraoka; Yoshimichi Sai; Nagao Suzuki; Akira Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

5.  Transport of peptidomimetic thrombin inhibitors with a 3-amidino-phenylalanine structure: permeability and efflux mechanism in monolayers of a human intestinal cell line (Caco-2).

Authors:  W Kamm; J Hauptmann; I Behrens; J Stürzebecher; F Dullweber; H Gohlke; M Stubbs; G Klebe; T Kissel
Journal:  Pharm Res       Date:  2001-08       Impact factor: 4.200

6.  Rhodamine 123 requires carrier-mediated influx for its activity as a P-glycoprotein substrate in Caco-2 cells.

Authors:  Matthew D Troutman; Dhiren R Thakker
Journal:  Pharm Res       Date:  2003-08       Impact factor: 4.200

7.  Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium.

Authors:  Matthew D Troutman; Dhiren R Thakker
Journal:  Pharm Res       Date:  2003-08       Impact factor: 4.200

8.  Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers.

Authors:  Matthew D Troutman; Dhiren R Thakker
Journal:  Pharm Res       Date:  2003-08       Impact factor: 4.200

9.  Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats.

Authors:  Kazuhiko Arimori; Noriaki Kuroki; Muneaki Hidaka; Tomomi Iwakiri; Keishi Yamsaki; Manabu Okumura; Hiroshige Ono; Norito Takamura; Masahiko Kikuchi; Masahiro Nakano
Journal:  Pharm Res       Date:  2003-06       Impact factor: 4.200

Review 10.  Mechanisms of clinically relevant drug interactions associated with tacrolimus.

Authors:  Uwe Christians; Wolfgang Jacobsen; Leslie Z Benet; Alfonso Lampen
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.